Reply: Pathophysiological Entity or Imaging-Based Risk Score?: A Controversial Interpretation of the Ratio

Michael I. Brener; Paul Grayburn; Michael J. Mack; Gregg W. Stone; Rebecca T. Hahn

doi:10.1016/j.jcin.2021.12.037

Reply: Pathophysiological Entity or Imaging-Based Risk Score?: A Controversial Interpretation of the Ratio

Michael I. Brener, Paul Grayburn, Michael J. Mack, Gregg W. Stone, Rebecca T. Hahn

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	346-347
Number of pages	2
Journal	JACC: Cardiovascular Interventions
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/j.jcin.2021.12.037
State	Published - 14 Feb 2022

Access to Document

10.1016/j.jcin.2021.12.037

Cite this

@article{5f636fcfadc14af69bcb41e4dbd3922a,

title = "Reply: Pathophysiological Entity or Imaging-Based Risk Score?: A Controversial Interpretation of the Ratio",

author = "Brener, {Michael I.} and Paul Grayburn and Mack, {Michael J.} and Stone, {Gregg W.} and Hahn, {Rebecca T.}",

note = "Funding Information: Dr Brener has received funding from National Institutes of Health grant NHLBI-T32HL007343. Dr Grayburn has received research grants from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Cardiovalve, W.L. Gore, Medtronic, and NeoChord; and has received consulting fees from Abbott Vascular, Edwards Lifesciences, W.L. Gore, and 4C Medical. Dr Mack served as co-primary investigator for the PARTNER trial for Edwards Lifesciences and the COAPT trial for Abbott, and has served as study chair for the APOLLO trial for Medtronic. Dr Stone has received speaker fees or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and CardioMech; and has equity and options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, the MedFocus family of funds, and Valfix. Dr Hahn has received speaker fees from Boston Scientific, Baylis Medical, Edwards Lifesciences, and Medtronic; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Edwards Lifesciences, Gore & Associates, Medtronic, and Philips Healthcare; has received nonfinancial support from 3mensio; holds equity with Navigate; and is the chief scientific officer for the echocardiography core laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Funding Information: Dr Brener has received funding from National Institutes of Health grant NHLBI-T32HL007343. Dr Grayburn has received research grants from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Cardiovalve, W.L. Gore, Medtronic, and NeoChord; and has received consulting fees from Abbott Vascular, Edwards Lifesciences, W.L. Gore, and 4C Medical. Dr Mack served as co-primary investigator for the PARTNER trial for Edwards Lifesciences and the COAPT trial for Abbott, and has served as study chair for the APOLLO trial for Medtronic. Dr Stone has received speaker fees or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and CardioMech; and has equity and options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, the MedFocus family of funds, and Valfix. Dr Hahn has received speaker fees from Boston Scientific, Baylis Medical, Edwards Lifesciences, and Medtronic; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Edwards Lifesciences, Gore & Associates, Medtronic, and Philips Healthcare; has received nonfinancial support from 3mensio; holds equity with Navigate; and is the chief scientific officer for the echocardiography core laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation.",

year = "2022",

month = feb,

day = "14",

doi = "10.1016/j.jcin.2021.12.037",

language = "English",

volume = "15",

pages = "346--347",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Reply

T2 - Pathophysiological Entity or Imaging-Based Risk Score?: A Controversial Interpretation of the Ratio

AU - Brener, Michael I.

AU - Grayburn, Paul

AU - Mack, Michael J.

AU - Stone, Gregg W.

AU - Hahn, Rebecca T.

N1 - Funding Information: Dr Brener has received funding from National Institutes of Health grant NHLBI-T32HL007343. Dr Grayburn has received research grants from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Cardiovalve, W.L. Gore, Medtronic, and NeoChord; and has received consulting fees from Abbott Vascular, Edwards Lifesciences, W.L. Gore, and 4C Medical. Dr Mack served as co-primary investigator for the PARTNER trial for Edwards Lifesciences and the COAPT trial for Abbott, and has served as study chair for the APOLLO trial for Medtronic. Dr Stone has received speaker fees or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and CardioMech; and has equity and options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, the MedFocus family of funds, and Valfix. Dr Hahn has received speaker fees from Boston Scientific, Baylis Medical, Edwards Lifesciences, and Medtronic; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Edwards Lifesciences, Gore & Associates, Medtronic, and Philips Healthcare; has received nonfinancial support from 3mensio; holds equity with Navigate; and is the chief scientific officer for the echocardiography core laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Funding Information: Dr Brener has received funding from National Institutes of Health grant NHLBI-T32HL007343. Dr Grayburn has received research grants from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Cardiovalve, W.L. Gore, Medtronic, and NeoChord; and has received consulting fees from Abbott Vascular, Edwards Lifesciences, W.L. Gore, and 4C Medical. Dr Mack served as co-primary investigator for the PARTNER trial for Edwards Lifesciences and the COAPT trial for Abbott, and has served as study chair for the APOLLO trial for Medtronic. Dr Stone has received speaker fees or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and CardioMech; and has equity and options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, the MedFocus family of funds, and Valfix. Dr Hahn has received speaker fees from Boston Scientific, Baylis Medical, Edwards Lifesciences, and Medtronic; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Edwards Lifesciences, Gore & Associates, Medtronic, and Philips Healthcare; has received nonfinancial support from 3mensio; holds equity with Navigate; and is the chief scientific officer for the echocardiography core laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation.

PY - 2022/2/14

Y1 - 2022/2/14

UR - http://www.scopus.com/inward/record.url?scp=85123736733&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2021.12.037

DO - 10.1016/j.jcin.2021.12.037

M3 - Letter

C2 - 35144796

AN - SCOPUS:85123736733

SN - 1936-8798

VL - 15

SP - 346

EP - 347

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 3

ER -